BIOCAPTIVA Secures US Patent for Advanced DNA-Extraction Technology in Cancer Management

BIOCAPTIVA, a biotech company based in Edinburgh, has been granted its first US patent for a liquid biopsy technology designed to efficiently capture cell-free DNA (cfDNA) directly from blood and other bodily fluids. This innovation is expected to enhance early disease detection, treatment monitoring, and personalized medicine.

Originating from research at the University of Edinburgh, BIOCAPTIVA's patented msX™ technology forms the core of the company’s product pipeline. The technology utilizes a library of polymer coatings capable of capturing cfDNA directly from biological fluids such as blood and plasma in greater quantities than current methods, eliminating the need for centrifugation and additional reagents. Additionally, the technology allows for the storage of cfDNA on-polymer at room temperature for up to 90 days, facilitating long-term analysis.

The patent covers both in-vivo and ex-vivo applications, including BIOCAPTIVA's BioCaptis device, which is designed to improve cancer management by capturing nucleic acids from large volumes of biological fluids. This capability broadens the potential applications of the technology beyond oncology, with implications for molecular diagnostics, personalized medicine, and biomedical research.

Jeremy Wheeler, CEO of BIOCAPTIVA, stated:

"This US patent grant is a crucial achievement for BIOCAPTIVA. It not only secures our intellectual property but also underscores the extensive potential of our technology, which we've been developing since spinning out of the University of Edinburgh in 2020. What began as a focused research project and a single medical device has evolved into a comprehensive platform with far-reaching implications for liquid biopsy and the broader biomedical industry."

Jeremy Wheeler, CEO co-founder, BIOCAPTIVA

Looking forward, BIOCAPTIVA plans to explore partnerships to expand the applications of its msX™ technology across various healthcare and research domains. The company aims to leverage its innovative approach to contribute to advancements in disease detection and personalized treatment strategies.

Topics: Tools & Methods